Buys | $20,755,667 | 6 | 67 |
Sells | $383,745 | 3 | 33 |
Cormorant Asset Management, LP | 10 percent owner | 2 | $20.57M | 0 | $0 | $20.57M |
Zaderej Karen L. | director | 1 | $99,750 | 0 | $0 | $99,750 |
ANDO GORAN | director | 1 | $39,750 | 0 | $0 | $39,750 |
Lurker Nancy | director | 1 | $25,003 | 0 | $0 | $25,003 |
DICICCO WENDY F | director | 1 | $19,997 | 0 | $0 | $19,997 |
GUYER DAVID R | director | 0 | $0 | 3 | $383,745 | $-383,745 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the …
Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $20.76M and sold $383,745 worth of EyePoint Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $22.43M and sold $43.05M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $20.57M. Zaderej Karen L. (director) — $99,750. ANDO GORAN (director) — $39,750.
The last purchase of 5,000 shares for transaction amount of $39,750 was made by ANDO GORAN (director) on 2024‑08‑21.
2024-08-21 | ANDO GORAN | director | 5,000 0.0082% | $7.95 | $39,750 | -8.56% | ||
2024-08-20 | DICICCO WENDY F | director | 2,567 0.0048% | $7.79 | $19,997 | +7.38% | ||
2024-08-19 | Zaderej Karen L. | director | 12,500 0.0235% | $7.98 | $99,750 | +4.22% | ||
2024-08-16 | Lurker Nancy | director | 3,173 0.0057% | $7.88 | $25,003 | +4.16% | ||
2024-07-12 | Sale | GUYER DAVID R | director | 11,625 0.0274% | $10.06 | $116,995 | -18.88% | |
2024-06-03 | Sale | GUYER DAVID R | director | 11,625 0.0233% | $10.30 | $119,705 | -13.16% | |
2024-05-14 | Sale | GUYER DAVID R | director | 11,625 0.0227% | $12.65 | $147,045 | -30.24% | |
2024-05-06 | Cormorant Asset Management, LP | 10 percent owner | 850,000 1.8064% | $11.86 | $10.08M | -22.28% | ||
2024-04-18 | Cormorant Asset Management, LP | 10 percent owner | 581,765 1.2029% | $18.03 | $10.49M | -50.00% | ||
2024-02-02 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 209 0.0007% | $28.49 | $5,954 | -67.70% | |
2024-01-26 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 26,017 0.0509% | $25.38 | $660,370 | -64.41% | |
2024-01-26 | Sale | Paggiarino Dario A. | Chief Medical Officer | 49,325 0.0975% | $25.66 | $1.27M | -64.41% | |
2024-01-25 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 600 0.0012% | $25.00 | $15,000 | -62.09% | |
2024-01-25 | Sale | Paggiarino Dario A. | Chief Medical Officer | 600 0.0012% | $25.00 | $15,000 | -62.09% | |
2024-01-24 | Sale | Lurker Nancy | Executive Vice Chair | 29,956 0.0887% | $24.98 | $748,250 | -60.48% | |
2024-01-24 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 11,300 0.0335% | $25.01 | $282,621 | -60.48% | |
2024-01-24 | Sale | Paggiarino Dario A. | Chief Medical Officer | 11,251 0.0334% | $25.01 | $281,415 | -60.48% | |
2024-01-23 | Sale | Lurker Nancy | Executive Vice Chair | 5,044 0.0144% | $24.97 | $125,950 | -61.98% | |
2024-01-23 | Sale | Jones David Scott | SVP & Chief Commercial Officer | 900 0.0026% | $25.00 | $22,500 | -61.98% | |
2024-01-23 | Sale | Paggiarino Dario A. | Chief Medical Officer | 5,135 0.0146% | $25.00 | $128,375 | -61.98% |
Cormorant Asset Management, LP | 10 percent owner | 8325000 12.1128% | $54.28M | 6 | 0 | <0.0001% |
Lurker Nancy | director | 97635 0.1421% | $636,580.20 | 4 | 4 | <0.0001% |
Zaderej Karen L. | director | 16500 0.024% | $107,580.00 | 1 | 0 | |
ANDO GORAN | director | 13150 0.0191% | $85,738.00 | 1 | 0 | |
DICICCO WENDY F | director | 9967 0.0145% | $64,984.84 | 1 | 0 |
$14,527,743 | 76 | 38.40% | $447.93M | |
$84,871,118 | 57 | 17.71% | $412.59M | |
$24,384,691 | 42 | -30.27% | $455.92M | |
$54,828,550 | 26 | -13.88% | $493.09M | |
$26,923,982 | 20 | -17.22% | $407.13M |
Increased Positions | 95 | +77.87% | 22M | +37.34% |
Decreased Positions | 49 | -40.16% | 6M | -10.54% |
New Positions | 30 | New | 7M | New |
Sold Out Positions | 23 | Sold Out | 2M | Sold Out |
Total Postitions | 168 | +37.7% | 74M | +26.8% |
Cormorant Asset Management, Lp | $52,198.00 | 12.24% | 8.32M | 0 | 0% | 2024-12-31 |
Suvretta Capital Management, Llc | $42,530.00 | 9.98% | 6.78M | +2M | +31.05% | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $36,053.00 | 8.46% | 5.75M | +2M | +51.66% | 2024-12-31 |
Blackrock, Inc. | $33,114.00 | 7.77% | 5.28M | +1M | +27.1% | 2024-12-31 |
Franklin Resources Inc | $25,943.00 | 6.09% | 4.14M | +125,519 | +3.13% | 2024-12-31 |
Vanguard Group Inc | $23,846.00 | 5.59% | 3.8M | +755,045 | +24.77% | 2024-12-31 |
Federated Hermes, Inc. | $23,246.00 | 5.45% | 3.71M | +2M | +92.73% | 2024-12-31 |
Tcg Crossover Management, Llc | $22,399.00 | 5.25% | 3.57M | +3M | +287.31% | 2024-12-31 |
Ra Capital Management, L.P. | $19,950.00 | 4.68% | 3.18M | +3M | New | 2024-12-31 |
Citadel Advisors Llc | $15,467.00 | 3.63% | 2.47M | +1M | +75.28% | 2024-12-31 |